The Glutamatergic System and Alzheimer’s Disease: Therapeutic Implications

Author： Butterfield D.A.   Pocernich C.B.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.17, Iss.9, 2003-01, pp. : 641-652

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apolipoprotein E and Alzheimer’s Disease: Therapeutic Implications

By Higuchi M.  

CNS Drugs, Vol. 11, Iss. 6, 1999-06 ,pp. : 411-420

Adis International

Access to resources Recommend Favorite

Potential therapeutic targets for Alzheimer’s disease

By McKeon-O’Malley C.   Saunders A.J.   Bush A.I.   Tanzi R.E.  

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 2, 1998-12 ,pp. : 157-179

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomics and therapeutic prospects in Alzheimer’s disease

By Cacabelos Ramón  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 1967-1987

Informa Healthcare

Access to resources Recommend Favorite

Intranasal therapeutic strategies for management of Alzheimer’s disease

By Sood Sumeet   Jain Kunal   Gowthamarajan K.  

Journal of Drug Targeting, Vol. 22, Iss. 4, 2014-05 ,pp. : 279-294

Informa Healthcare

Access to resources Recommend Favorite

New therapeutic patents for Alzheimer’s disease

By  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 12, 1998-12 ,pp. : 1751-1757

Informa Healthcare

Access to resources Recommend Favorite